Charles River Parisotto sells 981 shares after exercise

The executive's option exercise and share sale occurred under a Rule 10b5-1 Trading Plan adopted March 4, 2026.

Rhea-AI Filing Summary

Shannon M. Parisotto, CEVP, Disc & Safety Assessment at Charles River Laboratories International, Inc., exercised options to acquire 981 common shares at $208.44 per share and sold 981 shares at $308.44 per share on October 5, 2026. The exercise and sale occurred under a Rule 10b5-1 Trading Plan adopted March 4, 2026. After the exercise, 2,944 stock options remained. Reported indirect holdings included 9,680 common shares held by Trust and 28,510 common shares held by Karpathos Investments LLC.

Insider Trade Summary 10b5-1

Exercise and Sale: 981 shares ($98K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Parisotto Shannon M

Role CEVP, Disc & Safety Assessment

Sold 981 shs ($303K)

Approx. gross sale proceeds $303K

Approx. exercise cost $204K

Approx. pre-tax spread $98K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	981	$0.00	$0.00
Exercise	Common Stock	981	$208.44	$204K
Sale	Common Stock F1	981	$308.44	$303K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 2,944 contracts (Direct); Common Stock — 4,807 shares (Direct); Common Stock — 9,680 shares (Indirect, By Trust); Common Stock — 28,510 shares (Indirect, by Karpathos Investments LLC)

Footnotes (1)

1. F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted on March 4, 2026.

Key Figures

Options exercised: 981 options Exercise price: $208.44 per share Common shares sold: 981 shares +4 more

7 metrics

Options exercised 981 options Exercise reported October 5, 2026

Exercise price $208.44 per share Options exercised October 5, 2026

Common shares sold 981 shares Sale reported October 5, 2026

Sale price $308.44 per share Sale reported October 5, 2026

Stock options remaining 2,944 stock options Following the reported exercise

Indirect common shares held by Trust 9,680 shares Reported October 5, 2026

Indirect common shares held by Karpathos Investments LLC 28,510 shares Reported October 5, 2026

Key Terms

Rule 10b5-1 Trading Plan, Stock Options (Right to Buy)

2 terms

Rule 10b5-1 Trading Plan regulatory

"occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRL shares did Shannon M. Parisotto sell?

Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 981 common shares at $308.44 per share on October 5, 2026. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan adopted March 4, 2026.

How many CRL options did Shannon M. Parisotto exercise?

She exercised options to acquire 981 common shares at an exercise price of $208.44 per share on October 5, 2026. After the exercise, 2,944 stock options were reported as remaining.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 08:32 PM Accepted by SEC EDGAR 10/07/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parisotto Shannon M

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEVP, Disc & Safety Assessment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		M		981	A	$208.44	5,788	D
Common Stock	10/05/2026		S		981(1)	D	$308.44	4,807	D
Common Stock								9,680	I	By Trust
Common Stock								28,510	I	by Karpathos Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$208.44	10/05/2026		M			981	05/31/2025	05/31/2034	Common Stock	981	$0	2,944	D

Explanation of Responses:

1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted on March 4, 2026.

Remarks:

	/s/ Shannon M. Parisotto	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)